<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868462</url>
  </required_header>
  <id_info>
    <org_study_id>OPT1029</org_study_id>
    <nct_id>NCT03868462</nct_id>
  </id_info>
  <brief_title>Optos P200TE Agreement and Precision Study</brief_title>
  <official_title>Optos P200TE Agreement and Precision Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optos, PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optos, PLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective comparative, randomized, single center study to assess agreement&#xD;
      and precision of the Optos P200TE in comparison to the predicate device in normal subjects,&#xD;
      subjects with glaucoma, and subjects with retinal disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Actual">September 16, 2019</completion_date>
  <primary_completion_date type="Actual">September 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the Optos P200TE and predicate device measurements of full retinal thickness (μm).</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the Optos P200TE and predicate device measurements of retinal nerve fiber layer thickness (μm).</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the Optos P200TE and predicate device measurements of ganglion cell complex thickness (μm).</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the Optos P200TE and predicate device measurements of optic disc (area, volume, cup-to-disc ratio).</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the Optos P200TE and predicate device measurements of full retinal thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the Optos P200TE and predicate device measurements of retinal nerve fiber layer thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the Optos P200TE and predicate device measurements of ganglion cell complex thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the Optos P200TE and predicate device measurements of optic disc (area, volume, cup-to-disc ratio).</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision of the P200TE for the super pixel grid measurements of the full retinal thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision of the P200TE for the super pixel grid measurements of the RNFL thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision of the P200TE for the super pixel grid measurements of GCC thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Retinal Disease</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Optical Coherence Tomography (OCT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optos P200TE</intervention_name>
    <description>The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.</description>
    <arm_group_label>Optical Coherence Tomography (OCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Predicate Device</intervention_name>
    <description>The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.</description>
    <arm_group_label>Optical Coherence Tomography (OCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group&#xD;
&#xD;
          1. Subjects 22 years of age or older on the date of informed consent&#xD;
&#xD;
          2. Subjects able to understand the written informed consent and willing to participate as&#xD;
             evidenced by signing the informed consent&#xD;
&#xD;
          3. Subjects with normal eye examinations in both eyes on the date of the study visit as&#xD;
             observed with a 90 diopter lens&#xD;
&#xD;
          4. BCVA 20/40 or better (each eye) on the date of the study visit&#xD;
&#xD;
             Exclusion Criteria for Normal Group&#xD;
&#xD;
          5. Subjects unable to tolerate ophthalmic imaging&#xD;
&#xD;
          6. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images in&#xD;
             either eye&#xD;
&#xD;
          7. Presence of any ocular pathology except for cataract in either eye&#xD;
&#xD;
          8. History of leukemia, dementia or multiple sclerosis&#xD;
&#xD;
             Inclusion Criteria for Glaucoma Group&#xD;
&#xD;
          9. Subjects 22 years of age or older on the date of informed consent&#xD;
&#xD;
         10. Subjects able to understand the written informed consent and willing to participate as&#xD;
             evidenced by signing the informed consent&#xD;
&#xD;
         11. BCVA 20/40 or better in the study eye&#xD;
&#xD;
         12. History of Visual field defects within the previous six (6) months from the study&#xD;
             visit or measured the day of the study visit consistent with glaucomatous optic nerve&#xD;
             damage with at least one of the following two findings:&#xD;
&#xD;
               1. On pattern deviation (PD), there exists a cluster of 3 or more points in an&#xD;
                  expected location of the visual field depressed below the 5% level, at least 1 of&#xD;
                  which is depressed below the 1% level;&#xD;
&#xD;
               2. Glaucoma hemi-field test &quot;outside normal limits.&quot;&#xD;
&#xD;
         13. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or&#xD;
             retinal nerve fiber layer structural abnormalities:&#xD;
&#xD;
               1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim,&#xD;
                  especially at the inferior or superior poles with or without disc hemorrhage;&#xD;
&#xD;
               2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural&#xD;
                  tissue&#xD;
&#xD;
             Exclusion Criteria for Glaucoma Group&#xD;
&#xD;
         14. Subjects unable to tolerate ophthalmic imaging&#xD;
&#xD;
         15. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images in&#xD;
             the study eye&#xD;
&#xD;
         16. No reliable Humphrey Field Analyzer (HFA) visual field (24-2 Sita Standard, white on&#xD;
             white) result within 6 months of the study visit, defined as fixation losses &gt; 33% or&#xD;
             false positives &gt; 33%, or false negatives &gt; 33% in the study eye&#xD;
&#xD;
         17. Presence of any ocular pathology except glaucoma in the study eye&#xD;
&#xD;
         18. History of leukemia, dementia or multiple sclerosis&#xD;
&#xD;
             Inclusion Criteria for Retina Disease Group&#xD;
&#xD;
         19. Subjects 22 years of age or older on the date of informed consent&#xD;
&#xD;
         20. Subjects able to understand the written informed consent and willing to participate as&#xD;
             evidenced by signing the informed consent&#xD;
&#xD;
         21. Subjects presenting at the site with retinal disease&#xD;
&#xD;
         22. BCVA 20/400 or better in the study eye&#xD;
&#xD;
         23. Diagnosis of some type of retinal pathology by investigator, may include, but not&#xD;
             limited to: Macular Degeneration (including patients with drusen and geographic atropy&#xD;
             and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy,&#xD;
             Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others&#xD;
&#xD;
             Exclusion Criteria for Retinal Disease Group&#xD;
&#xD;
         24. Subjects unable to tolerate ophthalmic imaging&#xD;
&#xD;
         25. Subject with ocular media not sufficiently clear to obtain acceptable OCT images in&#xD;
             the study eye&#xD;
&#xD;
         26. Presence of glaucoma or any ocular pathology other than a retinal pathology (e.g.,&#xD;
             cornea pathology) in the study eye as determined by self-report and/or investigator&#xD;
             assessment at the study visit;&#xD;
&#xD;
         27. History of leukemia, dementia or multiple sclerosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New England Retina Consultants</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 2, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>October 13, 2019</last_update_submitted>
  <last_update_submitted_qc>October 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

